These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39174957)

  • 41. Hyperammonemia in a carbamoyl-phosphate synthetase 1 deficiency recipient after living-donor liver transplantation from a carrier donor: a case report.
    Kakiuchi T; Nosho T; Oka M; Tashiro K
    Front Med (Lausanne); 2023; 10():1327854. PubMed ID: 38235270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Application of Next-Generation Sequencing (NGS) in Neonatal-Onset Urea Cycle Disorders (UCDs): Clinical Course, Metabolomic Profiling, and Genetic Findings in Nine Chinese Hyperammonemia Patients.
    Zhou Q; Huang H; Ma L; Zhu T
    Biomed Res Int; 2020; 2020():5690915. PubMed ID: 32934962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A case of carbamoyl phosphate synthetase 1 deficiency presenting symptoms at one month of age.
    Ono H; Suto T; Kinoshita Y; Sakano T; Furue T; Ohta T
    Brain Dev; 2009 Nov; 31(10):779-81. PubMed ID: 19167850
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Living-donor liver transplantation for carbamoyl phosphate synthetase 1 deficiency.
    Kasahara M; Sakamoto S; Shigeta T; Fukuda A; Kosaki R; Nakazawa A; Uemoto S; Noda M; Naiki Y; Horikawa R
    Pediatr Transplant; 2010 Dec; 14(8):1036-40. PubMed ID: 21108709
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of citrulline substitution on clinical outcome after liver transplantation in carbamoyl phosphate synthetase 1 and ornithine transcarbamylase deficiency.
    Aldrian D; Waldner B; Vogel GF; El-Gharbawy AH; McKiernan P; Vockley J; Landau YE; Al Mutairi F; Stepien KM; Kwok AM; Yıldız Y; Honzik T; Kelifova S; Ellaway C; Lund AM; Mori M; Grünert SC; Scholl-Bürgi S; Zöggeler T; Oberhuber R; Schneeberger S; Müller T; Karall D
    J Inherit Metab Dis; 2024 Mar; 47(2):220-229. PubMed ID: 38375550
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precision medicine in rare disease: Mechanisms of disparate effects of N-carbamyl-l-glutamate on mutant CPS1 enzymes.
    Shi D; Zhao G; Ah Mew N; Tuchman M
    Mol Genet Metab; 2017 Mar; 120(3):198-206. PubMed ID: 28007335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel compound heterozygote variants: c.4193_4206delinsG (p.Leu1398Argfs*25), c.793C > A (p.Pro265Thr), in the CPS1 gene (NM_001875.4) causing late onset carbamoyl phosphate synthetase 1 deficiency-Lessons learned.
    Lin HT; Enchautegui-Colon Y; Huang YR; Zimmerman C; DeMarzo D; Tsai AC
    Mol Genet Metab Rep; 2022 Dec; 33():100942. PubMed ID: 36466970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term survival of a patient with acute neonatal-onset metabolic encephalopathy with carbamoyl phosphate synthetase 1 deficiency.
    Imataka G; Ishii J; Ando Y; Yoshihara S; Takagi Y; Nitta A; Arisaka O; Yoshihara S
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10051-10053. PubMed ID: 33090410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gene structure of human carbamylphosphate synthetase 1 and novel mutations in patients with neonatal onset.
    Häberle J; Schmidt E; Pauli S; Rapp B; Christensen E; Wermuth B; Koch HG
    Hum Mutat; 2003 Apr; 21(4):444. PubMed ID: 12655559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unraveling the therapeutic potential of carbamoyl phosphate synthetase 1 (CPS1) in human diseases.
    Zhang L; Zou Y; Lu Y; Li Z; Gao F
    Bioorg Chem; 2023 Jan; 130():106253. PubMed ID: 36356370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phytohemagglutinin stimulation of lymphocytes improves mutation analysis of carbamoylphosphate synthetase 1.
    Kretz R; Hu L; Wettstein V; Leiteritz D; Häberle J
    Mol Genet Metab; 2012 Jul; 106(3):375-8. PubMed ID: 22575620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Y-box binding protein-1 down-regulates expression of carbamoyl phosphate synthetase-I by suppressing CCAAT enhancer-binding protein-alpha function in mice.
    Chen YR; Sekine K; Nakamura K; Yanai H; Tanaka M; Miyajima A
    Gastroenterology; 2009 Jul; 137(1):330-40. PubMed ID: 19272383
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Yap S; Gougeard N; Hart AR; Barcelona B; Rubio V
    JIMD Rep; 2019 Jul; 48(1):36-44. PubMed ID: 31392111
    [No Abstract]   [Full Text] [Related]  

  • 54. 3-Methylglutaconic aciduria, a frequent but underrecognized finding in carbamoyl phosphate synthetase I deficiency.
    Rokicki D; Pajdowska M; Trubicka J; Thong MK; Ciara E; Piekutowska-Abramczuk D; Pronicki M; Sikora R; Haidar R; Ołtarzewski M; Jabłońska E; Muthukumarasamy P; Sthaneswar P; Gan CS; Krajewska-Walasek M; Carrozzo R; Verrigni D; Semeraro M; Rizzo C; Taurisano R; Alhaddad B; Kovacs-Nagy R; Haack TB; Dionisi-Vici C; Pronicka E; Wortmann SB
    Clin Chim Acta; 2017 Aug; 471():95-100. PubMed ID: 28526534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The activity of the carbamoyl phosphate synthase 1 promoter in human liver-derived cells is dependent on hepatocyte nuclear factor 3-beta.
    Chen Z; Tang N; Wang X; Chen Y
    J Cell Mol Med; 2017 Sep; 21(9):2036-2045. PubMed ID: 28272778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic effect of
    Sugiyama Y; Shimura M; Ogawa-Tominaga M; Ebihara T; Kinouchi Y; Isozaki K; Matsuhashi T; Tajika M; Fushimi T; Ichimoto K; Matsunaga A; Ishida T; Mizutani K; Tsuruoka T; Murayama K
    Mol Genet Metab Rep; 2020 Sep; 24():100622. PubMed ID: 32670798
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical course of 63 patients with neonatal onset urea cycle disorders in the years 2001-2013.
    Unsinn C; Das A; Valayannopoulos V; Thimm E; Beblo S; Burlina A; Konstantopoulou V; Mayorandan S; de Lonlay P; Rennecke J; Derbinski J; Hoffmann GF; Häberle J
    Orphanet J Rare Dis; 2016 Aug; 11(1):116. PubMed ID: 27538463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loss of Hep Par 1 immunoreactivity in the livers of patients with carbamoyl phosphate synthetase 1 deficiency.
    Yamaguchi M; Kataoka TR; Shibayama T; Fukuda A; Nakazawa A; Minamiguchi S; Sakurai T; Miyagawa-Hayashino A; Yorifuji T; Kasahara M; Uemoto S; Haga H
    Pathol Int; 2016 Jun; 66(6):333-6. PubMed ID: 27150549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Carbamoyl phosphate synthetase I deficiency: molecular genetic findings and prenatal diagnosis.
    Aoshima T; Kajita M; Sekido Y; Mimura S; Itakura A; Yasuda I; Saheki T; Watanabe K; Shimokata K; Niwa T
    Prenat Diagn; 2001 Aug; 21(8):634-7. PubMed ID: 11536261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.